Form 4: Amgen Director Acquires Shares Under 10b5-1 Plan

Amgen Director Omar Ishrak acquired 218.6134 shares of common stock at no cost, increasing his beneficial ownership.

Summary

• Amgen Inc. Director Omar Ishrak acquired 218.6134 shares of the company's common stock.
• The transaction occurred on November 7, 2025, and was executed at a price of $0 per share, indicating a grant or award rather than a market purchase.
• This acquisition was made pursuant to a Rule 10b5-1(c) pre-arranged trading plan.
• Following this transaction, Mr. Ishrak beneficially owns a total of 6,507.5436 shares of Amgen common stock.
• The total beneficial ownership includes 338 Dividend Equivalents (DEs) granted under the Director Program, which are paid out in shares of common stock.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as a director is increasing their stake in the company, even if through a grant. This aligns management's interests with shareholders. However, it's a routine transaction and not indicative of significant new developments.

Positives

• Director Omar Ishrak increased his beneficial ownership in Amgen Inc., aligning his interests further with shareholders.
• The transaction was conducted under a Rule 10b5-1(c) plan, indicating a pre-scheduled and transparent acquisition strategy.

Future Outlook

NA

Industry Context

This is a routine insider transaction for a director of a major biotechnology company. Such grants are common forms of executive and director compensation in the pharmaceutical and biotech industries, aiming to align leadership interests with long-term company performance.

Comparison to Industry Standards

• The acquisition of shares at a $0 price is standard practice for equity compensation (e.g., restricted stock unit vesting or performance share grants) for directors and executives across the biotechnology and broader corporate sectors.
• The use of a Rule 10b5-1 plan for such transactions is a common corporate governance practice, providing an affirmative defense against insider trading allegations by pre-scheduling trades.

Stakeholder Impact

• Shareholders: The director's increased ownership aligns their interests with long-term shareholder value.
• Employees: No direct impact on employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated.

Key Dates

Keywords

Amgen, AMGN, Omar Ishrak, Director, Insider Transaction, Form 4, Share Acquisition, Equity Compensation, 10b5-1 Plan